#2 - CRSPR Therapeutics (NASDAQ:CRSP)
CRSPR Therapeutics AG (NASDAQ: CRSP) is a leader in the field of gene editing. This is becoming a closely watched sector for investors. CRSPR shows how AI, combined with the company's existing CRISPR/Cas 9 platform, provides more precision for modifying gene mutations.
AI is also a powerful tool for gene prediction since it can analyze a large quantity of data and create a knowledge model. Ideally, this will speed up the development of new cancer treatments and vaccine development.
In 2024, CRSPR, in partnership with Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX), received FDA approval, the first-of-its-kind for a CRISPR-based medicine. Casgevy is a gene-editing drug for sickle-cell disease.
CRSP stock has been up 56% in the last 12 months, with much of that gain coming in the last six months in anticipation of FDA approval. However, the stock is up 101% in the last five years and analysts are beginning to raise their price targets for the stock.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More - Current Price
- $46.29
- Consensus Rating
- Hold
- Ratings Breakdown
- 9 Buy Ratings, 8 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $74.94 (61.9% Upside)
